2021
DOI: 10.17157/mat.8.2.5122
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Sovereignty: Building a Blood Screening Test for the Brazilian Nation

Abstract: This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country’s blood screening programme. The concept of ‘molecular sovereignty’ is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to support local knowledge production as a means of advancing national he… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 21 publications
0
3
0
1
Order By: Relevance
“…Esse foco no produto final também negligencia outras vulnerabilidades. Uma delas é a necessidade de infraestruturas para desenvolvimento e produção de novas vacinas e testes 8 . Algumas iniciativas vêm buscando suprir essas lacunas, como o Centro Henrique Penna, de Bio-Manguinhos, que conta com uma planta piloto, o Centro de Produção Multipropósito de Vacinas do Instituto Butantã, com uma área de nível de segurança 3, e a previsão do Centro Nacional de Vacinas do Ministério da Ciência, Tecnologia e Inovação.…”
Section: Vacinas E Testes De Diagnósticounclassified
“…Esse foco no produto final também negligencia outras vulnerabilidades. Uma delas é a necessidade de infraestruturas para desenvolvimento e produção de novas vacinas e testes 8 . Algumas iniciativas vêm buscando suprir essas lacunas, como o Centro Henrique Penna, de Bio-Manguinhos, que conta com uma planta piloto, o Centro de Produção Multipropósito de Vacinas do Instituto Butantã, com uma área de nível de segurança 3, e a previsão do Centro Nacional de Vacinas do Ministério da Ciência, Tecnologia e Inovação.…”
Section: Vacinas E Testes De Diagnósticounclassified
“…This focus on the final product also overlooks other vulnerabilities. One is the need for infrastructure to develop and produce new vaccines and tests 8 . Some initiatives have sought to address these gaps, such as Bio-Manguinhos’ Henrique Penna Center, which has a pilot plant; Butantã’s Multipurpose Vaccine Production Center, which provides for a security level 3 area; and the future National Vaccine Center of the Brazilian Ministry of Science Technology and Innovation.…”
Section: Vaccines and Diagnostic Testsmentioning
confidence: 99%
“…Bio-Manguinhos, the Institute of Technology on Immunobiologicals, is one example; in fact, this public laboratory was the second-largest supplier of the Montenegro skin test to the Brazilian Ministry of Health until 2003, when the CPPI became the only supplier. Bio-Manguinhos stopped producing the LST because it is so inexpensive and simple to manufacture, preferring to focus on higher value-added products that augment revenue and streamline the manufacturing process 6 . The LST is indeed very cheap: in 2015, the Ministry of Health paid only 7.00 BRL for each kit 7 .…”
mentioning
confidence: 99%